araag2/HINT huggingface dataset:
Clinical trial NCT02392234 (phase 3, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: vx-661/ivacaftor, ivacaftor, placebo matched to vx-661/ ivacaftor, placebo matched to ivacaftor
SMILES: CC(C)(CO)C1=CC2=CC(NC(=O)C3(CC3)C3=CC=C4OC(F)(F)OC4=C3)=C(F)C=C2N1C[C@@H](O)CO, CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Heterozygous for F508del-CFTR and a second allele with a CFTR mutation predicted to
             have residual function

          -  Forced Expiratory Volume in 1 Second (FEV1) greater than or equal to (≥) 40 percent
             (%) and less than or equal to (≤) 90% of predicted normal for age, sex, and height
             during screening

          -  Sweat chloride value ≥60 millimole per liter (mmol/L) during screening OR as
             documented in the participant's medical record

          -  Stable CF disease as judged by the investigator

        Exclusion Criteria:

          -  History of any comorbidity that, in the opinion of the investigator, might confound
             the results of the study or pose an additional risk in administering study drug to the
             participant

          -  An acute upper or lower respiratory infection, pulmonary exacerbation

          -  History of solid organ or hematological transplantation

          -  Ongoing or prior participation in an investigational drug study (including studies
             investigating VX-661, lumacaftor [VX-809], and/or ivacaftor) within 30 days of
             screening

          -  Pregnant and nursing females

          -  Sexually active participants of reproductive potential who are not willing to follow
             the contraception requirements
Clinical trial NCT02396316 (phase 3, status: completed)
Conditions: glaucoma, neovascular
ICD codes: H16.401, H16.402, H16.403, H16.409, H26.211, H26.212, H26.213
Drugs: aflibercept (eylea, bay 86-5321), sham injection
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Japanese men and women aged 20 years or older,

          -  Patients diagnosed as having Neovascular glaucoma (NVG) with neovascularization in the
             anterior segment (both iris and anterior chamber angle),

          -  Patients with Intraocular pressure (IOP) higher than 25 mmHg in the study eye due to
             anterior segment (both iris and anterior chamber angle) neovascularization.

        Exclusion Criteria:

          -  Patients with angle-closure due to conditions other than Neovascular glaucoma

          -  Patients with a known or suspected ocular or peri-ocular infection,

          -  Patients with severe intraocular inflammation in the study eye,

          -  Women who are pregnant, suspected of being pregnant or lactating,

          -  Patients with known allergy to aflibercept.
Clinical trial NCT02397473 (phase 3, status: completed)
Conditions: episodic cluster headache
ICD codes: G44.011, G44.019
Drugs: galcanezumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have a diagnosis of cluster headache as defined by International Headache Society
             (IHS) International Classification of Headache Disorders (ICHD)-3 beta guidelines with
             a history of episodic cluster headache with at least two cluster periods lasting from
             7 days to 1 year (when untreated) and separated by pain-free remission periods of >=1
             month.

          -  Participants are able to distinguish cluster headache attacks from other headaches.

        Exclusion Criteria:

          -  Current enrollment in or discontinuation within the last 30 days from, a clinical
             trial involving any investigational drug or device.

          -  Current use or any prior exposure to any calcitonin-gene-related peptide (CGRP)
             antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF).

          -  Are taking indomethacin and/or are suspected of having another distinct trigeminal
             autonomic cephalalgia.

          -  A history of migraine variants that could implicate or could be confused with
             ischemia.

          -  Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic
             proteins.

          -  A history or presence of other medical illness that indicates a medical problem that
             would preclude study participation.

          -  Evidence of significant active or unstable psychiatric disease, in the opinion of the
             investigator.

          -  Women who are pregnant or nursing.
Clinical trial NCT02401243 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin glargine (u300)
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion criteria:

          -  Patients with type 2 diabetes mellitus.

          -  Patients who are ≥18 years of age.

          -  Treated for diabetes for at least 6 months.

               -  If on basal insulin, stable for at least 3 months prior to screening visit on
                  their basal insulin treatment(s) (±20% total insulin dose)

               -  If on NIAHA, stable for at least 8 weeks prior to screening visit on their
                  NIAHA(s) (no change in dose or initiation of new NIAHAs).

          -  Patients on uncontrolled basal insulin (insulin glargine, normal protamine Hagedorn
             [NPH], detemir) +/ NIAHAs with an A1c >7.0% and ≤10% or uncontrolled on NIAHAs
             (insulin naïve patients) with an A1c >7.0% and ≤11%.

          -  Signed informed consent form.

        Exclusion criteria:

          -  Patients with type 1 diabetes mellitus (T1DM).

          -  Nightshift worker.

          -  Female patients who are pregnant or lactating.

          -  Treatment with an insulin other than basal insulin (premixes, rapid insulin, fast
             acting insulin analogues) within the previous 3 months.

          -  Patients with less than 1 year history of diabetes.

          -  Patients unwilling to inject insulin or perform self-monitoring blood glucose.

          -  Current alcohol or drug abuse.

          -  Patients unlikely to comply with the protocol and complete the study eg, uncooperative
             attitude, inability to return for follow-up visits.

          -  Patients with active cancer or any other diseases or conditions which in the opinion
             of the Investigator would make the patient unsuitable for participation in the study.

          -  Any clinically significant laboratory findings that in the judgment of the
             Investigator would preclude safe completion of the study.

          -  Known allergies to study drugs.

          -  Participation in another clinical study.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT02403401 (phase 3, status: completed)
Conditions: contraception
ICD codes: Z92.0, Z30.012, Z30.09
Drugs: levonorgestrel (bay98-7196)
SMILES: [H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy female subject requesting contraception and willing to use the IVR

          -  Normal or clinically insignificant cervical smear not requiring further follow up (a
             cervical smear has to be taken at screening visit or a normal result has to be
             documented within the previous 6 months)

          -  History of regular cyclic menstrual periods

          -  Subject is willing and able to attend the scheduled study visits and comply with study
             procedures

        Exclusion Criteria:

          -  Pregnancy or lactation (less than three months since delivery, abortion, or lactation
             before start of treatment)

          -  Any diseases or conditions that can compromise the function of the body systems and
             could result in altered absorption, excessive accumulation, impaired metabolism, or
             altered excretion of the study drug

          -  Any diseases or conditions that might interfere with the conduct of the study or the
             interpretation of the results

          -  Any disease or condition that may worsen under hormonal treatment according to the
             assessment and opinion of the investigator

          -  Undiagnosed abnormal genital bleeding

          -  Wish for pregnancy during the study

          -  Major surgery scheduled during the study period
Clinical trial NCT02403674 (phase 3, status: active, not recruiting)
Conditions: human immunodeficiency virus (hiv)
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: doravirine, tenofovir, lamivudine, atripla™, placebo
SMILES: CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Is HIV-1 positive as determined by a positive result on an enzyme-immunoassay, has
             screening plasma HIV-1 RNA (determined by the central laboratory) ≥1000 copies/mL
             within 45 days prior to the treatment phase of this study, and has HIV treatment
             indicated based on physician assessment

          -  Has never received antiretroviral therapy (ART)

          -  Is highly unlikely to either become pregnant or impregnate a partner

        Exclusion Criteria:

          -  Has a history or current evidence of any condition, therapy, laboratory abnormality,
             or other circumstance that might confound results of the study

          -  Is a user of recreational or illicit drugs or has a recent history of alcohol/drug
             abuse

          -  Has been treated for a viral infection other than HIV-1 (e.g., hepatitis B) with an
             agent that is active against HIV-1

          -  Has participated in a study with an investigational drug/device within 30 days prior
             to Screening

          -  Has used systemic immunosuppressive therapy or immune modulators within 30 days prior
             to treatment in this study or is anticipated to need them during the course of the
             study

          -  Has a current (active) diagnosis of acute hepatitis due to any cause (note:
             participants with chronic hepatitis B and C may enter the study as long as they
             fulfill all entry criteria, have stable liver function tests, and have no significant
             impairment of hepatic synthetic function)

          -  Is a female who is pregnant, breastfeeding, or expecting to conceive

          -  Is a female and is expecting to donate eggs or is male and is expecting to donate
             sperm (investigators will provide appropriate guidance regarding egg and/or sperm
             donation after completion of the study treatment regimen)

          -  Has evidence of decompensated liver disease manifested by the presence of or a history
             of ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy or other
             signs or symptoms of advanced liver diseases, or has liver cirrhosis and a Child-Pugh
             Class C score or Pugh-Turcotte (CPT) score > 9
Clinical trial NCT02404363 (phase 3, status: terminated)
Conditions: locally advanced pancreatic cancer, adenocarcinoma, pancreas, metastatic pancreatic cancer
ICD codes: C25.3, C25.3
Drugs: clopidogrel, placebo
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    recruitment problem
  
Eligibility criteria:

        Inclusion Criteria:

          -  18 years of age or older

          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas

          -  Locally advanced or metastatic pancreatic cancer

          -  Measurable primary pancreatic cancer or metastasis

          -  No previous chemotherapy either in an adjuvant or metastatic setting

          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

          -  Adequate bone marrow: granulocyte count ≥ 1.5 G/L; and platelet count ≥ 100 G/L

          -  Adequate liver function: bilirubin ≤ 2 times the upper limit of the normal range,
             transaminases (AST and ALT) ≤ 3 times the upper limit of the normal range

          -  Adequate renal function: calculated clearance rate > 60 m.mn-1 (Estimated glomerular
             filtration rate using Modification of Diet in Renal Disease (MDRD) formula or
             Cockcroft-Gault formula)

          -  Women of childbearing potential must use an effective birth control method

        Exclusion Criteria:

          -  Endocrine or acinar pancreatic carcinoma

          -  Pancreatic metastasis of other primary tumors

          -  Previous radiotherapy for measurable lesions

          -  Previous chemotherapy

          -  History of brain metastases, uncontrolled spinal cord compression, or carcinomatous
             meningitis

          -  Other prior malignancy. Adequately treated basal cell or squamous cell skin cancer,
             carcinoma in situ of the cervix or any other cancer from which the patient has been
             disease free for > 5 years are allowed.

          -  Known HIV disease requiring antiretroviral treatment

          -  Hemorrhagic diathesis

          -  Aspirin with a daily dose > 75 mg

          -  Curative dose of LMWH

          -  Recent venous thromboembolism (< 1 year)

          -  Patients under VKA

          -  Lesion of the digestive tract that could be hemorrhagic with clopidogrel treatment

          -  Active infection

          -  Chronic diarrhea

          -  Cardiac disease with a left ventricular ejection fraction below 45%

          -  Hypersensitivity to clopidogrel or its excipients

          -  Patients with severe hepatic impairment

          -  Patients who are pregnant or breast feeding, or who are not using effective birth
             control methods

          -  Participation in another clinical research protocol, participation in a trial of
             routine care is authorized at the same time as PANCREADOGREL

          -  Patient under tutorship or curatorship

          -  Patients unwilling or unable to comply with the protocol

          -  Not affiliated to health system ("bénéficiaire ou ayant droit")
Clinical trial NCT02405039 (phase 3, status: unknown status)
Conditions: dry eye
ICD codes: H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, H35.3121
Drugs: ebi-005, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          1. Have a history of dry eye disease (DED) in both eyes supported by a previous clinical
             diagnosis or have a self-reported history of subjective complaints for at least 6
             months prior to Visit 1

          2. Are willing and able to follow instructions and can be present for the required study
             visits for the duration of the study

        Key Exclusion Criteria:

          1. Have an ocular condition that could confound study assessments (ocular infection,
             herpetic or neurotrophic keratitis, Steven-Johnson Syndrome, etc)

          2. Have had penetrating intraocular surgery within 12 months prior to Visit 1

          3. Be unwilling to comply with the study requirements
Clinical trial NCT02405091 (phase 3, status: completed)
Conditions: tardive dyskinesia
ICD codes: K22.4, G24.01
Drugs: nbi-98854
SMILES: COC1=C(OC)C=C2[C@H]3C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN3CCC2=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Subjects of childbearing potential must agree to use hormonal or two forms of
             nonhormonal contraception (dual contraception) consistently during the screening,
             treatment and follow-up periods of the study.

          2. Female subjects must not be pregnant.

          3. Have one of the following clinical diagnoses for at least 3 months prior to screening:
             Schizophrenia or Schizoaffective Disorder, or Mood Disorder

          4. Have a clinical diagnosis of neuroleptic-induced TD for at least 3 months prior to
             screening.

          5. Have moderate or severe TD

          6. If using maintenance medication(s) for schizophrenia or schizoaffective disorder, or
             mood disorder, be on stable doses.

          7. Be in general good health.

          8. Have adequate hearing, vision, and language skills to perform the procedures specified
             in the protocol.

          9. Have a negative urine drug screen for amphetamines, barbiturates, benzodiazepine,
             phencyclidine, cocaine, opiates, or cannabinoids.

        Exclusion Criteria

          1. Have an active, clinically significant unstable medical condition within 1 month prior
             to screening.

          2. Have a known history of substance dependence, substance (drug) or alcohol abuse.

          3. Have a significant risk of suicidal or violent behavior.

          4. Have a known history of neuroleptic malignant syndrome.

          5. Have a known history of long QT syndrome or cardiac tachy-arrhythmia.

          6. Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed).

          7. Have received an investigational drug within 30 days before screening or plan to use
             an investigational drug (other than NBI-98854) during the study.

          8. Have a blood loss ≥550 mL or donated blood within 30 days prior to Baseline.

          9. Have an allergy, hypersensitivity, or intolerance to tetrabenazine.

         10. Are currently pregnant or breastfeeding.
Clinical trial NCT02407236 (phase 3, status: active, not recruiting)
Conditions: colitis, ulcerative, inflammatory bowel diseases
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811, M06.4, G61.89, G61.9, M35.81, G61.81, K75.9, M27.2
Drugs: placebo iv, placebo sc, ustekinumab iv, ustekinumab sc
SMILES: [Na+].[Cl-], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Has a clinical diagnosis of Ulcerative Colitis (UC) at least 3 months before Screening

          -  Has moderately to severely active UC, defined as a Baseline (Week 0) Mayo score of 6
             to 12, including a Screening endoscopy subscore of the Mayo score greater than or
             equal to (>=) 2 as determined by a central reading of the video endoscopy

          -  Have failed biologic therapy, that is, have received treatment with 1 or more tumour
             necrosis factor (TNF) antagonists or vedolizumab at a dose approved for the treatment
             of UC, and have a documented history of failure to respond to or tolerate such
             treatment; OR Be naïve to biologic therapy (TNF antagonists or vedolizumab) or have
             received biologic therapy but have not demonstrated a history of failure to respond
             to, or tolerate, a biologic therapy and have a prior or current UC medication history
             that includes at least 1 of the following: a. Inadequate response to or failure to
             tolerate current treatment with oral corticosteroids or immunomodulators
             (6-mercaptopurine [6-MP] or azathioprine [AZA]) OR b. History of failure to respond
             to, or tolerate, at least 1 of the following therapies: oral or IV corticosteroids or
             immunomodulators (6-MP or AZA) OR c. History of corticosteroid dependence (that is, an
             inability to successfully taper corticosteroids without a return of the symptoms of
             UC)

          -  Before the first administration of study agent, the following conditions must be met:
             vedolizumab must have been discontinued for at least 4 months and anti-tumor necrosis
             factors (TNFs) for at least 8 weeks

        Exclusion Criteria:

          -  Has severe extensive colitis and is at imminent risk of colectomy

          -  Has UC limited to the rectum only or to < 20 centimeters (cm) of the colon

          -  Presence of a stoma or history of a fistula

          -  Participants with history of extensive colonic resection (for example, less than 30 cm
             of colon remaining) that would prevent adequate evaluation of the effect of study
             agent on clinical disease activity

          -  Participants with history of colonic mucosal dysplasia. Participants will not be
             excluded from the study because of a pathology finding of "indefinite dysplasia with
             reactive atypia''
Clinical trial NCT02409342 (phase 3, status: active, not recruiting)
Conditions: non-squamous non-small cell lung cancer, squamous non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: atezolizumab (mpdl3280a) [tecentriq], an engineered anti-pdl1 antibody, carboplatin, cisplatin, gemcitabine, pemetrexed
SMILES: CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed, Stage IV non-squamous or squamous NSCLC

          -  No prior treatment for Stage IV non-squamous or squamous NSCLC. Participant known to
             have a sensitizing mutation in the epidermal growth factor receptor (EGFR) gene or an
             anaplastic lymphoma kinase (ALK) fusion oncogene are excluded from the study

          -  Tumor PD-L1 expression as determined by immunohistochemistry (IHC) assay of archival
             tumor tissue or tissue obtained at screening

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1

          -  Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST
             v1.1)

          -  Adequate hematologic and end-organ function

        Exclusion Criteria:

          -  Known sensitizing mutation in the EGFR gene or ALK fusion oncogene

          -  Active or untreated central nervous system (CNS) metastases as determined by Computed
             Tomography (CT) or magnetic resonance imaging (MRI) evaluation

          -  Malignancies other than NSCLC within 5 years prior to randomization, with the
             exception of those with a negligible risk of metastasis or death treated with expected
             curative outcome

          -  Pregnant or lactating women

          -  History of autoimmune disease

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening
             chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is
             permitted

          -  Positive test for Human Immunodeficiency Virus (HIV)

          -  Active hepatitis B or hepatitis C

          -  Prior treatment with cluster of differentiation (CD) 137 agonists or immune checkpoint
             blockade therapies, anti PD1, and anti-PD-L1 therapeutic antibody

          -  Severe infection within 4 weeks prior to randomization

          -  Significant history of cardiovascular disease